BioPharmX Announces Therapeutic Dermatology Advisory Board
MENLO PARK, Calif., Feb. 25, 2016 /PRNewswire/ -- BioPharmX Corporation (NYSE MKT: BPMX) today announced the formation of a Therapeutic Dermatology Advisory Board composed of seven dermatology thought leaders who together bring years of experience in clinical care, academia and research treating all forms of acne. They will provide strategic counsel to BioPharmX, a Silicon Valley-based specialty pharmaceutical company, as it develops products to address unmet dermatology needs.
BioPharmX is currently developing a novel topical gel formulation of minocycline, known as BPX-01, for the treatment of acne vulgaris, which has shown promise in pre-clinical studies. All advisory board members have ...!-->!-->